Personalized Melphalan Formulations and Delivery Systems for Next-Generation Cancer Treatment

The present inventive concept envisions a paradigm shift in melphalan-based cancer treatment by integrating personalized formulations, AI-driven predictive modeling, and innovative delivery systems to enhance treatment efficacy and patient outcomes.

The original patent provides stable ready-to-use injectable formulations of melphalan, but limitations in terms of personalized treatment, optimal dosage, and administration routes remain. The present inventive concept addresses these limitations by introducing a system that combines melphalan formulations with enhanced stability and companion diagnostic tools, as well as innovative delivery methods, such as wearable devices and nanocarrier-based formulations.

The inventive concept comprises multiple components: 1) a system for personalized cancer treatment, integrating melphalan formulations with enhanced stability and companion diagnostic tools for identifying optimal dosage and administration routes; 2) a method for generating patient-specific melphalan formulations using artificial intelligence-driven predictive modeling and real-time monitoring of treatment efficacy; 3) a modular, wearable device for continuous, transdermal delivery of melphalan, featuring a micro-needles array and a programmable drug reservoir; 4) a nanocarrier-based melphalan formulation for targeted, intratumoral delivery, wherein the nanocarriers are engineered to respond to specific tumor microenvironment cues; and 5) a closed-loop, implantable system for real-time monitoring and adaptive control of melphalan delivery, comprising a biosensor, a microcontroller, and a drug delivery module. These components work in tandem to provide a comprehensive, patient-centric approach to cancer treatment.

The present inventive concept introduces a novel combination of personalized formulations, AI-driven predictive modeling, and innovative delivery systems, which collectively represent a significant departure from the original patent's focus on stable ready-to-use injectable formulations. The inventive concept's emphasis on patient-specific treatment, real-time monitoring, and adaptive control of melphalan delivery constitutes a substantial and non-obvious advancement in the field.

Alternative embodiments of the inventive concept could include variations in the companion diagnostic tools, such as incorporating additional biomarkers or using different AI algorithms. The wearable device could be modified to accommodate different types of cancer or patient populations. The nanocarrier-based formulation could be adapted for use with other anti-cancer agents or in combination with other therapeutic modalities.

The present inventive concept has significant commercial potential in the oncology market, particularly in the areas of personalized medicine and targeted cancer therapies. The market for cancer treatment is projected to continue growing, driven by increasing incidence rates and the need for more effective treatment options. The inventive concept's focus on patient-centric, adaptive, and targeted therapies positions it for significant market share and potential partnerships with pharmaceutical companies, research institutions, and healthcare providers.